← All Dianthus Therapeutics, INC /DE/ filings

Dianthus Therapeutics, INC /DE/ 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
DNTH
Dianthus Therapeutics, INC /DE/
10-K: Dianthus Therapeutics Reports 2024 Financial Results and Provides Business Update
Dianthus Therapeutics continues to advance its clinical-stage complement therapeutic, DNTH103, while reporting a net loss of $85.0 million for the year ended December 31, 2024.
NASDAQ
DNTH
Dianthus Therapeutics, INC /DE/
10-K: Dianthus Therapeutics Outlines Capital Structure and Regulatory Framework in 10-K Filing
Dianthus Therapeutics' 10-K filing details its capital stock structure, anti-takeover provisions, and regulatory compliance, highlighting its focus on developing complement therapeutics.